Taysha Gene Therapies (NASDAQ:TSHA) Receives "Overweight" Rating from Cantor Fitzgerald

Cantor Fitzgerald restated their overweight rating on shares of Taysha Gene Therapies (NASDAQ:TSHA - Free Report) in a research note published on Tuesday morning, Benzinga reports. Cantor Fitzgerald currently has a $7.00 target price on the stock.

TSHA has been the topic of several other reports. Needham & Company LLC reiterated a buy rating and issued a $7.00 price objective on shares of Taysha Gene Therapies in a research note on Thursday, April 11th. JMP Securities reissued a market outperform rating and set a $5.00 price objective on shares of Taysha Gene Therapies in a research report on Wednesday, March 20th. Piper Sandler assumed coverage on shares of Taysha Gene Therapies in a report on Tuesday, April 9th. They issued an overweight rating and a $9.00 target price on the stock. Canaccord Genuity Group reiterated a buy rating and set a $7.00 price target on shares of Taysha Gene Therapies in a report on Thursday, March 21st. Finally, Chardan Capital raised their price objective on shares of Taysha Gene Therapies from $5.00 to $7.00 and gave the company a buy rating in a report on Thursday, March 21st. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has a consensus rating of Buy and a consensus target price of $6.88.

Taysha Gene Therapies Trading Down 0.8 %

TSHA stock traded down $0.02 during mid-day trading on Tuesday, hitting $2.43. 1,170,933 shares of the company were exchanged, compared to its average volume of 2,545,641. The business has a fifty day simple moving average of $2.65 and a 200-day simple moving average of $2.09. The firm has a market capitalization of $454.45 million, a P/E ratio of -3.63 and a beta of 0.29. Taysha Gene Therapies has a 12-month low of $0.50 and a 12-month high of $3.89. The company has a quick ratio of 4.08, a current ratio of 4.08 and a debt-to-equity ratio of 0.54.

Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report) last released its quarterly earnings results on Tuesday, March 19th. The company reported $0.35 EPS for the quarter. The firm had revenue of $3.60 million for the quarter, compared to analysts' expectations of $4.75 million. On average, equities research analysts predict that Taysha Gene Therapies will post -0.39 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Taysha Gene Therapies

A number of hedge funds have recently modified their holdings of the business. China Universal Asset Management Co. Ltd. increased its stake in Taysha Gene Therapies by 66.1% in the first quarter. China Universal Asset Management Co. Ltd. now owns 35,908 shares of the company's stock valued at $103,000 after purchasing an additional 14,286 shares during the period. Cannon Global Investment Management LLC acquired a new stake in Taysha Gene Therapies during the 1st quarter worth approximately $69,000. Chicago Partners Investment Group LLC grew its stake in shares of Taysha Gene Therapies by 21.4% in the 4th quarter. Chicago Partners Investment Group LLC now owns 134,851 shares of the company's stock valued at $239,000 after purchasing an additional 23,740 shares during the last quarter. ADAR1 Capital Management LLC acquired a new position in shares of Taysha Gene Therapies in the fourth quarter valued at approximately $370,000. Finally, Avoro Capital Advisors LLC raised its stake in shares of Taysha Gene Therapies by 11.0% during the fourth quarter. Avoro Capital Advisors LLC now owns 4,355,555 shares of the company's stock worth $7,709,000 after purchasing an additional 430,555 shares during the last quarter. 77.70% of the stock is currently owned by hedge funds and other institutional investors.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.